All In Biotech

NDA 050138 · King Pharms LLC

Bicillin C-R

Penicillin G Benzathine, Penicillin G Procaine · Injection

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1953

May 18, 1953

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

802

170 Phase 3, 84 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Penicillin G Benzathine" as an intervention, any sponsor and status, largest first.

All 802 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Bicillin C-R (Pen G Benz/Pen G Procaine) · HCPCS J0558

2024 spending

$13K

Beneficiaries

66

92 claims

Per beneficiary

$191

2024 ASP limit $18.50 per unit

View as table
YearSpending
2020$65,854
2021$49,969
2022$53,529
2023$64,314
2024$12,615

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: King Pharms LLC · Also marketed as Bicillin C-R 900/300

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.